Printer Friendly

BIOSYS ANNOUNCES CONTRACT MANUFACTURING AGREEMENT WITH CIBA-GEIGY

 PALO ALTO, Calif., May 6 /PRNewswire/ -- biosys (NASDAQ: BIOS), a biopesticide company, today announced the signing of a multi-year contract manufacturing agreement with Ciba-Geigy Corp., United States (Ciba), Ardsley, N.Y., under which biosys will produce a variety of strains of B.t. (Bacillus thuringiensis), the active ingredient in the Ciba Plant Protection Division's biopesticide product line. The agreement underscores biosys' strategy to leverage its strengths in fermentation and formulation technologies by developing manufacturing relationships with third parties.
 "The Ciba/biosys agreement exemplifies biosys' capability to provide high-quality, cost-competitive fermentation technology scale-up and implementation," said Patrick Simms, senior vice president, manufacturing, at biosys.
 Initial manufacturing campaigns were successfully conducted by biosys prior to ratification of the multi-year agreement between the two companies.
 "Ciba and biosys bring complementary strengths to this partnership. Our customers will ultimately benefit through better products," said John Barnett, vice president, Insect Control Business Unit at Ciba.
 The agreement grants biosys exclusive rights to produce B.t. for Ciba's U.S. needs. International product requirements are also expected to be produced by biosys under this agreement.
 biosys is a leader in the development and commercialization of biological pesticides for the control of a wide range of insect pests. Using advanced science and technology, the company develops and manufactures biological controls that are effective in commercial usage. biosys holds patents for the manufacture of beneficial nematodes in liquid fermentation and their formulation for commercial use.
 Ciba Plant Protection is a division of Ciba-Geigy Corp. Headquartered in Greensboro, N.C., the division is an industry leader in the development, production and marketing of agricultural crop protection products for insect, weed and disease control.
 -0- 5/6/93
 /CONTACT: Patrick Simms, senior vice president, or Bruce G. Fielding Jr., senior vice president and chief financial officer, of biosys, 415-856-9500/
 (BIOS)


CO: biosys; Ciba-Geigy Corp. ST: California, New York IN: MTC SU:

GT-LM -- SJ002 -- 5196 05/06/93 08:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1993
Words:320
Previous Article:LA JOLLA PHARMACEUTICAL LAUNCHES INFLAMMATION PROGRAM
Next Article:WAL-MART STORES, INC. REPORTS APRIL SALES
Topics:


Related Articles
BIOSYS AND CIBA-GEIGY REACH R&D FUNDING AND MARKETING AGREEMENT
BIOSYS REPORTS FIRST QUARTER RESULTS
biosys REPORTS SECOND QUARTER RESULTS
CAMBRIDGE NEUROSCIENCE, INC. APPOINTS FORMER CIBA-GEIGY CLINICAL RESEARCH DIRECTOR AS VICE PRESIDENT, CLINICAL STUDIES
ONCOGENE SCIENCE, CIBA-GEIGY AND PFIZER INK PACT FOR PRODUCTION, DEVELOPMENT AND MARKETING OF PROTEIN-BASED DRUG
MYCOGEN, CIBA SEEDS EXPAND LICENSING, DEVELOPMENT AGREEMENT FOR INSECT-RESISTANT CORN
CIBA SEEDS RESPONDS TO PGS' INTELLECTUAL PROPERTY CHALLENGE
ISIS AND CIBA FINALIZE MAJOR EXPANDED ANTISENSE RESEARCH AND DEVELOPMENT AGREEMENT; A SECOND CANCER COMPOUND SET TO ENTER PHASE I CLINICAL TRIALS
CIBA-GEIGY LIMITED AND NEUROCRINE BIOSCIENCES, INC. SIGN AGREEMENT TO COLLABORATE ON MULTIPLE SCLEROSIS TREATMENT
ALTUS BIOLOGICS ENTERS COLLABORATION WITH CIBA-GEIGY TO DEVELOP HIGH PERFORMANCE ENZYMES FOR DETERGENT APPLICATIONS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters